Results 171 to 180 of about 1,265,387 (249)

Określanie pola

, 2021
openaire   +1 more source

Rozległe pola

, 2018
openaire   +2 more sources

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. [PDF]

J Clin Oncol
Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trněný M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Batlevi CL, Tilly H, Flowers CR.   +36 more
europepmc   +1 more source

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti-CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Zhang Y, Ren Y, Zhuang J, Yuan L, Wang Z, Zhang X, Wang W, Cheng Z, Cheng L, Li J, Liu P.   +10 more
europepmc   +1 more source

Pola millenovecentoventi

Quaderni, 1977
openaire   +2 more sources

Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China. [PDF]

Sci Rep
Li M, Li Q, Zhang Y, Xu C, Chen Z, Huang Y, Jiang L.   +6 more
europepmc   +1 more source